Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.

van Montfort T, van der Sluis R, Darcis G, Beaty D, Groen K, Pasternak AO, Pollakis G, Vink M, Westerhout EM, Hamdi M, Bakker M, van der Putten B, Jurriaans S, Prins JH, Jeeninga R, Thomas AAM, Speijer D, Berkhout B.

EBioMedicine. 2019 Apr;42:97-108. doi: 10.1016/j.ebiom.2019.02.014. Epub 2019 Feb 26.

2.

Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries.

Popa C, Holvoet K, Van Montfort T, Groeneveld F, Simoens S.

Front Pharmacol. 2018 Oct 1;9:1108. doi: 10.3389/fphar.2018.01108. eCollection 2018.

3.

Dendritic cells as natural latency reversing agent: A wake-up call for HIV-1.

van Montfort T, Speijer D, Berkhout B.

Virulence. 2017 Nov 17;8(8):1494-1497. doi: 10.1080/21505594.2017.1371898. Epub 2017 Sep 28. No abstract available.

4.

Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.

Sliepen K, van Montfort T, Ozorowski G, Pritchard LK, Crispin M, Ward AB, Sanders RW.

Biomolecules. 2015 Oct 23;5(4):2919-34. doi: 10.3390/biom5042919.

5.

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.

Sliepen K, Ozorowski G, Burger JA, van Montfort T, Stunnenberg M, LaBranche C, Montefiori DC, Moore JP, Ward AB, Sanders RW.

Retrovirology. 2015 Sep 26;12:82. doi: 10.1186/s12977-015-0210-4.

6.

Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody.

van Montfort T, Thomas AA, Krawczyk PM, Berkhout B, Sanders RW, Paxton WA.

J Immunol. 2015 Oct 15;195(8):3759-68. doi: 10.4049/jimmunol.1402344. Epub 2015 Sep 9.

7.

Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.

Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien JP, Lee JH, van Montfort T, de Taeye SW, Connors M, Burton DR, Wilson IA, Klasse PJ, Ward AB, Moore JP, Sanders RW.

PLoS Pathog. 2015 Mar 25;11(3):e1004767. doi: 10.1371/journal.ppat.1004767. eCollection 2015 Mar.

8.

Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes.

Stax MJ, Mouser EE, van Montfort T, Sanders RW, de Vries HJ, Dekker HL, Herrera C, Speijer D, Pollakis G, Paxton WA.

PLoS One. 2015 Mar 20;10(3):e0122020. doi: 10.1371/journal.pone.0122020. eCollection 2015.

9.

Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment.

van der Sluis RM, van Capel TM, Speijer D, Sanders RW, Berkhout B, de Jong EC, Jeeninga RE, van Montfort T.

AIDS. 2015 Jun 1;29(9):1003-14. doi: 10.1097/QAD.0000000000000637.

PMID:
25768834
10.

Immunosilencing a highly immunogenic protein trimerization domain.

Sliepen K, van Montfort T, Melchers M, Isik G, Sanders RW.

J Biol Chem. 2015 Mar 20;290(12):7436-42. doi: 10.1074/jbc.M114.620534. Epub 2015 Jan 29.

11.

Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.

Isik G, Sliepen K, van Montfort T, Sanders RW.

PLoS One. 2014 Sep 23;9(9):e107683. doi: 10.1371/journal.pone.0107683. eCollection 2014.

12.

Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Isik G, van Montfort T, Chung NP, Moore JP, Sanders RW.

J Immunol. 2014 May 15;192(10):4628-35. doi: 10.4049/jimmunol.1303401. Epub 2014 Apr 11.

13.

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien JP, Wilson IA, Klasse PJ, Ward AB, Moore JP.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18256-61. doi: 10.1073/pnas.1314351110. Epub 2013 Oct 21.

14.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. doi: 10.1371/journal.pone.0067484. Print 2013.

15.

An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells.

Isik G, Chung NP, van Montfort T, Menis S, Matthews K, Schief WR, Moore JP, Sanders RW.

PLoS One. 2013 Jun 24;8(6):e67309. doi: 10.1371/journal.pone.0067309. Print 2013.

16.

Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.

Isik G, van Montfort T, Boot M, Cobos Jiménez V, Kootstra NA, Sanders RW.

PLoS One. 2013;8(4):e60126. doi: 10.1371/journal.pone.0060126. Epub 2013 Apr 2.

17.

Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes.

van der Sluis RM, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B, Jeeninga RE.

PLoS Pathog. 2013 Mar;9(3):e1003259. doi: 10.1371/journal.ppat.1003259. Epub 2013 Mar 21.

18.

HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120.

Hoorelbeke B, van Montfort T, Xue J, LiWang PJ, Tanaka H, Igarashi Y, Van Damme EJ, Sanders RW, Balzarini J.

FEBS Lett. 2013 Apr 2;587(7):860-6. doi: 10.1016/j.febslet.2013.02.037. Epub 2013 Feb 26.

19.

Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120.

van Montfort T, Sanders RW.

Expert Rev Vaccines. 2012 Oct;11(10):1175-7. doi: 10.1586/erv.12.102.

PMID:
23176650
20.

Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity.

van der Sluis RM, van Montfort T, Centlivre M, Schopman NC, Cornelissen M, Sanders RW, Berkhout B, Jeeninga RE, Paxton WA, Pollakis G.

J Virol Methods. 2013 Jan;187(1):94-102. doi: 10.1016/j.jviromet.2012.09.019. Epub 2012 Oct 8.

PMID:
23059551
21.

Selective packaging of cellular miRNAs in HIV-1 particles.

Schopman NC, van Montfort T, Willemsen M, Knoepfel SA, Pollakis G, van Kampen A, Sanders RW, Haasnoot J, Berkhout B.

Virus Res. 2012 Nov;169(2):438-47. doi: 10.1016/j.virusres.2012.06.017. Epub 2012 Jun 21.

PMID:
22728443
22.

HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

van Montfort T, Eggink D, Boot M, Tuen M, Hioe CE, Berkhout B, Sanders RW.

J Immunol. 2011 Nov 1;187(9):4676-85. doi: 10.4049/jimmunol.1101876. Epub 2011 Sep 28.

23.

Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):206-14. doi: 10.1089/aid.2011.0101. Epub 2011 Jul 27.

24.

A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.

Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP, Sanders RW.

Retrovirology. 2011 Jun 20;8:48. doi: 10.1186/1742-4690-8-48.

25.

A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

van Montfort T, Melchers M, Isik G, Menis S, Huang PS, Matthews K, Michael E, Berkhout B, Schief WR, Moore JP, Sanders RW.

J Biol Chem. 2011 Jun 24;286(25):22250-61. doi: 10.1074/jbc.M111.229625. Epub 2011 Apr 22.

26.

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.

Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW.

Virology. 2010 Jun 5;401(2):236-47. doi: 10.1016/j.virol.2010.02.019. Epub 2010 Mar 21. Erratum in: Virology. 2010 Oct 10;406(1):162-3.

27.

Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes.

Stax MJ, van Montfort T, Sprenger RR, Melchers M, Sanders RW, van Leeuwen E, Repping S, Pollakis G, Speijer D, Paxton WA.

Virology. 2009 Sep 1;391(2):203-11. doi: 10.1016/j.virol.2009.06.011.

28.

Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.

van Montfort T, Thomas AA, Pollakis G, Paxton WA.

J Virol. 2008 Aug;82(16):7886-96. doi: 10.1128/JVI.00245-08. Epub 2008 Jun 4.

29.

Increased virus replication in mammalian cells by blocking intracellular innate defense responses.

de Vries W, Haasnoot J, van der Velden J, van Montfort T, Zorgdrager F, Paxton W, Cornelissen M, van Kuppeveld F, de Haan P, Berkhout B.

Gene Ther. 2008 Apr;15(7):545-52. doi: 10.1038/gt.2008.12. Epub 2008 Feb 14.

PMID:
18273055
30.

Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes.

van Montfort T, Nabatov AA, Geijtenbeek TB, Pollakis G, Paxton WA.

J Immunol. 2007 Mar 1;178(5):3177-85.

31.

Supplemental Content

Loading ...
Support Center